The Sigma Enigma: A Narrative Review of Sigma Receptors

The sigma-1 and sigma-2 receptors were first discovered in the 1960s and were thought to be a form of opioid receptors initially. Over time, more was gradually learned about these receptors, which are actually protein chaperones, and many of their unique or unusual properties can contribute to a range of important new therapeutic applications. These sigma receptors translocate in the body and regulate calcium homeostasis and mitochondrial bioenergetics and they also have neuroprotective effects. The ligands to which these sigma receptors respond are several and dissimilar, including neurosteroids, neuroleptics, and cocaine. There is controversy as to their endogenous ligands. Sigma receptors are also involved in the complex processes of cholesterol homeostasis and protein folding. While previous work on this topic has been limited, research has been conducted in multiple disease states, such as addiction, aging. Alzheimer’s disease, cancer, psychiatric disorders, pain and neuropathic pain, Parkinson's disease, and others. There is currently increasing interest in sigma-1 and sigma-2 receptors as they provide potential therapeutic targets for many disease indications.

[1]  Ding Lin,et al.  Amyloid Cascade Hypothesis for the Treatment of Alzheimer’s Disease: Progress and Challenges , 2022, Aging and disease.

[2]  Xin Wang,et al.  The Impact of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis , 2022, Cells.

[3]  M. Tambuwala,et al.  Overview of therapeutic targets in management of dementia. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  C. Hetz,et al.  Cell death regulation by MAMs: from molecular mechanisms to therapeutic implications in cardiovascular diseases , 2022, Cell Death & Disease.

[5]  Taher Entezari-Maleki,et al.  Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists , 2022, Molecular Psychiatry.

[6]  E. Giovannetti,et al.  New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4 , 2022, Molecules.

[7]  F. Vizeacoumar,et al.  Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells , 2021, Pathogens.

[8]  E. Lacivita,et al.  σ2 Receptor and Its Role in Cancer with Focus on a MultiTarget Directed Ligand (MTDL) Approach , 2021, Molecules.

[9]  A. Marais Apolipoprotein E and Atherosclerosis , 2021, Current Atherosclerosis Reports.

[10]  M. Prasanth,et al.  The emerging role of the sigma-1 receptor in autophagy: hand-in-hand targets for the treatment of Alzheimer’s , 2021, Expert opinion on therapeutic targets.

[11]  G. Rishton,et al.  Sigma‐2 receptor antagonists rescue neuronal dysfunction induced by Parkinson’s patient brain‐derived α‐synuclein , 2020, Journal of neuroscience research.

[12]  K. Fukunaga,et al.  Wildtype σ1 receptor and the receptor agonist improve ALS-associated mutation-induced insolubility and toxicity. , 2020, The Journal of biological chemistry.

[13]  S. Regen The Origin of Lipid Rafts. , 2020, Biochemistry.

[14]  Taolei Sun,et al.  Sigma-2 Receptor—A Potential Target for Cancer/Alzheimer’s Disease Treatment via Its Regulation of Cholesterol Homeostasis , 2020, Molecules.

[15]  K. Fukunaga,et al.  Wildtype sigma-1 receptor and the receptor agonist improve ALS-associated mutation-induced insolubility and toxicity. , 2020, The Journal of biological chemistry.

[16]  C. Belzung,et al.  Cholesterol homeostasis: researching a dialogue between the brain and peripheral tissues. , 2020, Pharmacological research.

[17]  R. Mach,et al.  The Biological Function of Sigma-2 Receptor/TMEM97 and Its Utility in PET Imaging Studies in Cancer , 2020, Cancers.

[18]  D. Rossi,et al.  The sigma-1 receptor antagonists, promising players in fighting neuropathic pain. , 2020, Pharmaceutical patent analyst.

[19]  Hongwei Yu,et al.  Sigma-1 receptor activity in primary sensory neurons is a critical driver of neuropathic pain , 2020, Gene Therapy.

[20]  Frederick A. Heberle,et al.  Lipid Rafts: Controversies Resolved, Mysteries Remain. , 2020, Trends in cell biology.

[21]  L. Scorrano,et al.  The cell biology of mitochondrial membrane dynamics , 2020, Nature Reviews Molecular Cell Biology.

[22]  I. Jou,et al.  Lipids and Alzheimer’s Disease , 2020, International journal of molecular sciences.

[23]  S. Kourrich,et al.  The Sigma-1 Receptor: When Adaptive Regulation of Cell Electrical Activity Contributes to Stimulant Addiction and Cancer , 2019, Front. Neurosci..

[24]  K. Dill,et al.  Proteostasis collapse is a driver of cell aging and death , 2019, Proceedings of the National Academy of Sciences.

[25]  Ming-Chin Lin,et al.  Association between Use of Statin and Risk of Dementia: A Meta-Analysis of Observational Studies , 2019, Neuroepidemiology.

[26]  H. Schmidt,et al.  The Molecular Function of σ Receptors: Past, Present, and Future. , 2019, Trends in pharmacological sciences.

[27]  Yuanbo Wu,et al.  Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling. , 2019, Mitochondrion.

[28]  P. Cottone,et al.  Role of Sigma Receptors in Alcohol Addiction , 2019, Front. Pharmacol..

[29]  L. Romero,et al.  Trends in Sigma-1 Receptor Research: A 25-Year Bibliometric Analysis , 2019, Front. Pharmacol..

[30]  C. Chiang,et al.  Sigma-2 receptor/TMEM97 agonist PB221 as an alternative drug for brain tumor , 2019, BMC cancer.

[31]  D. Zamanillo,et al.  Blockade of the Sigma-1 Receptor Relieves Cognitive and Emotional Impairments Associated to Chronic Osteoarthritis Pain , 2019, Front. Pharmacol..

[32]  R. González-Ramírez,et al.  Molecular Interplay Between the Sigma-1 Receptor, Steroids, and Ion Channels , 2019, Front. Pharmacol..

[33]  Sungkwon Chung,et al.  Elevated cellular cholesterol in Familial Alzheimer’s presenilin 1 mutation is associated with lipid raft localization of β-amyloid precursor protein , 2019, PloS one.

[34]  Darjus F. Tschaharganeh,et al.  p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression , 2019, Cell.

[35]  Colin W. Taylor,et al.  Choline Is an Intracellular Messenger Linking Extracellular Stimuli to IP3-Evoked Ca2+ Signals through Sigma-1 Receptors , 2019, Cell reports.

[36]  I. Danovitch,et al.  Pain and Depression: A Systematic Review , 2018, Harvard review of psychiatry.

[37]  K. Bollinger,et al.  Sigma 1 receptor: A novel therapeutic target in retinal disease , 2018, Progress in Retinal and Eye Research.

[38]  F. Berardi,et al.  Sigma-2 receptor: past, present and perspectives on multiple therapeutic exploitations. , 2018, Future medicinal chemistry.

[39]  J. Bruna,et al.  Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathy , 2018, Neural regeneration research.

[40]  A. Carvalho,et al.  Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis , 2018, Scientific Reports.

[41]  G. Bu,et al.  Apolipoprotein E, Receptors, and Modulation of Alzheimer’s Disease , 2018, Biological Psychiatry.

[42]  Guillaume Thibault,et al.  From the unfolded protein response to metabolic diseases – lipids under the spotlight , 2018, Journal of Cell Science.

[43]  M. Hiriart,et al.  TRPV1 channels and the progesterone receptor Sig-1R interact to regulate pain , 2018, Proceedings of the National Academy of Sciences.

[44]  D. Engblom,et al.  The Sigma-2 Receptor Selective Agonist Siramesine (Lu 28-179) Decreases Cocaine-Reinforced Pavlovian Learning and Alters Glutamatergic and Dopaminergic Input to the Striatum , 2017, Front. Pharmacol..

[45]  Xiaojing Ma,et al.  Role of sigma 1 receptor in high fat diet-induced peripheral neuropathy , 2017, Biological chemistry.

[46]  T. Su,et al.  Roles of sigma-1 receptors on mitochondrial functions relevant to neurodegenerative diseases , 2017, Journal of Biomedical Science.

[47]  M. Merlos,et al.  The Sigma-1 Receptor Antagonist, S1RA, Reduces Stroke Damage, Ameliorates Post-Stroke Neurological Deficits and Suppresses the Overexpression of MMP-9 , 2017, Molecular Neurobiology.

[48]  C. Hetz,et al.  ER stress and the unfolded protein response in neurodegeneration , 2017, Nature Reviews Neurology.

[49]  D. Leroith,et al.  Elevated tumor LDLR expression accelerates LDL cholesterol-mediated breast cancer growth in mouse models of hyperlipidemia , 2017, Oncogene.

[50]  P. Cottone,et al.  Sigma Receptors and Alcohol Use Disorders. , 2016, Handbook of experimental pharmacology.

[51]  J. Vela,et al.  Blockade of sigma 1 receptors alleviates sensory signs of diabetic neuropathy in rats , 2016, European journal of pain.

[52]  H. Schmidt,et al.  Structural Perspectives on Sigma-1 Receptor Function. , 2017, Advances in experimental medicine and biology.

[53]  K. Hashimoto,et al.  Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders. , 2017, Advances in experimental medicine and biology.

[54]  B. Lucke-Wold,et al.  Sigma-1 Receptors and Neurodegenerative Diseases: Towards a Hypothesis of Sigma-1 Receptors as Amplifiers of Neurodegeneration and Neuroprotection. , 2017, Advances in experimental medicine and biology.

[55]  Jing Zhao,et al.  The Role of Sigma 1 Receptor as a Neuroprotective Target in Glaucoma. , 2017, Advances in experimental medicine and biology.

[56]  D. Grimm,et al.  Reduction of TMEM97 increases NPC1 protein levels and restores cholesterol trafficking in Niemann-pick type C1 disease cells , 2016, Human molecular genetics.

[57]  H. Schmidt,et al.  Crystal structure of the human σ1 receptor , 2016, Nature.

[58]  Prashant Mishra,et al.  Metabolic regulation of mitochondrial dynamics , 2016, The Journal of cell biology.

[59]  A. Ruoho,et al.  Biochemical Pharmacology of the Sigma-1 Receptor , 2016, Molecular Pharmacology.

[60]  C. Rousseaux,et al.  Sigma receptors [σRs]: biology in normal and diseased states , 2015, Journal of receptor and signal transduction research.

[61]  D. Schwarz,et al.  The endoplasmic reticulum: structure, function and response to cellular signaling , 2015, Cellular and Molecular Life Sciences.

[62]  F. Mollinedo,et al.  Lipid rafts as major platforms for signaling regulation in cancer. , 2015, Advances in biological regulation.

[63]  K. Fukunaga,et al.  The role of SIGMAR1 gene mutation and mitochondrial dysfunction in amyotrophic lateral sclerosis. , 2015, Journal of pharmacological sciences.

[64]  M. Portero-Otín,et al.  Lipidomics of human brain aging and Alzheimer's disease pathology. , 2015, International review of neurobiology.

[65]  Nidhi Kaushal,et al.  Sigma receptors as potential therapeutic targets for neuroprotection. , 2014, European journal of pharmacology.

[66]  E. Schon,et al.  Mitochondrial Genetics and Disease , 2014, Journal of child neurology.

[67]  Zong-Wen Wu,et al.  Sigma‐2 Receptor Ligands and Their Perspectives in Cancer Diagnosis and Therapy , 2014, Medicinal research reviews.

[68]  Jennifer G. Robinson,et al.  Higher RBC EPA + DHA corresponds with larger total brain and hippocampal volumes , 2014, Neurology.

[69]  I. Astsaturov,et al.  Molecular Pathways Molecular Pathways : Sterols and Receptor Signaling in Cancer , 2013 .

[70]  J. Huber,et al.  SN79, a sigma receptor ligand, blocks methamphetamine-induced microglial activation and cytokine upregulation , 2013, Experimental Neurology.

[71]  S. Kourrich,et al.  Dynamic Interaction between Sigma-1 Receptor and Kv1.2 Shapes Neuronal and Behavioral Responses to Cocaine , 2013, Cell.

[72]  D. Zamanillo,et al.  Role of sigma-1 receptors in paclitaxel-induced neuropathic pain in mice. , 2012, The journal of pain : official journal of the American Pain Society.

[73]  G. Pasternak Preclinical pharmacology and opioid combinations. , 2012, Pain medicine.

[74]  C. Hetz The unfolded protein response: controlling cell fate decisions under ER stress and beyond , 2012, Nature Reviews Molecular Cell Biology.

[75]  R. Hotchkiss,et al.  Sigma-2 ligands induce tumour cell death by multiple signalling pathways , 2012, British Journal of Cancer.

[76]  F. Al-Mohanna,et al.  A mutation in sigma‐1 receptor causes juvenile amyotrophic lateral sclerosis , 2011, Annals of neurology.

[77]  R. Hotchkiss,et al.  Characterization and Evaluation of Two Novel Fluorescent Sigma-2 Receptor Ligands as Proliferation Probes , 2011, Molecular imaging.

[78]  K. Nagata,et al.  Protein folding and quality control in the ER. , 2011, Cold Spring Harbor perspectives in biology.

[79]  M. Hayden,et al.  Cholesterol metabolism in Huntington disease , 2011, Nature Reviews Neurology.

[80]  P. Gressens,et al.  The Yin and Yang of Microglia , 2011, Developmental Neuroscience.

[81]  S. Buch,et al.  The sigma-1 receptor chaperone as an inter-organelle signaling modulator. , 2010, Trends in pharmacological sciences.

[82]  V. Perry,et al.  Microglia in neurodegenerative disease , 2010, Nature Reviews Neurology.

[83]  K. Hashimoto Can the sigma-1 receptor agonist fluvoxamine prevent schizophrenia? , 2009, CNS & neurological disorders drug targets.

[84]  Tangui Maurice,et al.  The pharmacology of sigma-1 receptors. , 2009, Pharmacology & therapeutics.

[85]  P. Daley,et al.  Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter , 2009, Journal of Neural Transmission.

[86]  Teruo Hayashi,et al.  Sigma-1 receptor chaperones and diseases. , 2009, Central nervous system agents in medicinal chemistry.

[87]  S. Kulkarni,et al.  σ-1 receptors in major depression and anxiety , 2009, Expert review of neurotherapeutics.

[88]  J. Entrena,et al.  Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands , 2008, Current neuropharmacology.

[89]  M. Ohyama,et al.  Low density of sigma1 receptors in early Alzheimer’s disease , 2008, Annals of nuclear medicine.

[90]  E. Aydar,et al.  Sigma-1 receptors bind cholesterol and remodel lipid rafts in breast cancer cell lines. , 2007, Cancer research.

[91]  Teruo Hayashi,et al.  Sigma-1 Receptor Chaperones at the ER- Mitochondrion Interface Regulate Ca2+ Signaling and Cell Survival , 2007, Cell.

[92]  Søren Vang,et al.  Protein misfolding and human disease. , 2006, Annual review of genomics and human genetics.

[93]  H. Hauri,et al.  The ER-Golgi intermediate compartment (ERGIC): in search of its identity and function , 2006, Journal of Cell Science.

[94]  R. Matsumoto,et al.  Involvement of sigma (σ) receptors in the acute actions of methamphetamine: Receptor binding and behavioral studies , 2005, Neuropharmacology.

[95]  J. Cedarbaum Survival , 2004 .

[96]  Teruo Hayashi,et al.  σ‐1 Receptors potentiate epidermal growth factor signaling towards neuritogenesis in PC12 cells: Potential relation to lipid raft reconstitution , 2004, Synapse.

[97]  Teruo Hayashi,et al.  σ-1 Receptors (σ1 Binding Sites) Form Raft-Like Microdomains and Target Lipid Droplets on the Endoplasmic Reticulum: Roles in Endoplasmic Reticulum Lipid Compartmentalization and Export , 2003, Journal of Pharmacology and Experimental Therapeutics.

[98]  L. Thal,et al.  Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology , 2003, Neurology.

[99]  W. Bowen,et al.  ς1 Receptor-Related Neuroactive Steroids Modulate Cocaine-Induced Reward , 2003, The Journal of Neuroscience.

[100]  D. Newmeyer,et al.  Mitochondria Releasing Power for Life and Unleashing the Machineries of Death , 2003, Cell.

[101]  K. Zou,et al.  Amyloid β‐protein affects cholesterol metabolism in cultured neurons: Implications for pivotal role of cholesterol in the amyloid cascade , 2002, Journal of neuroscience research.

[102]  P. Romieu,et al.  Sigma1 (σ1) receptor antagonists represent a new strategy against cocaine addiction and toxicity , 2002, Neuroscience & Biobehavioral Reviews.

[103]  W. Bowen,et al.  Involvement of sigma receptors in the behavioral effects of cocaine: evidence from novel ligands and antisense oligodeoxynucleotides , 2002, Neuropharmacology.

[104]  G. Pasternak,et al.  Sigma1 receptor modulation of opioid analgesia in the mouse. , 2002, The Journal of pharmacology and experimental therapeutics.

[105]  P. Romieu,et al.  Sigma(1) (sigma(1)) receptor antagonists represent a new strategy against cocaine addiction and toxicity. , 2002, Neuroscience and biobehavioral reviews.

[106]  A. Johnson,et al.  The translocon: a dynamic gateway at the ER membrane. , 1999, Annual review of cell and developmental biology.

[107]  G. Pasternak,et al.  Enhanced κ-opioid receptor-mediated analgesia by antisense targeting the σ1 receptor , 1997 .

[108]  H. Glossmann,et al.  High affinity of sigma1‐binding sites for sterol isomerization inhibitors: evidence for a pharmacological relationship with the yeast sterol C8–C7 isomerase , 1997, British journal of pharmacology.

[109]  E. Kempner,et al.  Purification, molecular cloning, and expression of the mammalian sigma1-binding site. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[110]  K. Jansen,et al.  Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell loss , 1993, Brain Research.

[111]  M. Brownstein A brief history of opiates, opioid peptides, and opioid receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[112]  R. Mulkey,et al.  Action potentials must admit calcium to evoke transmitter release , 1991, Nature.

[113]  W. Bowen,et al.  Sigma receptors: biology and function. , 1990, Pharmacological reviews.

[114]  C. Montigny,et al.  N-methyl-D-aspartate-induced neuronal activation is selectively modulated by σ receptors , 1990 .

[115]  E. London,et al.  Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. , 1988, Science.

[116]  S. Snyder,et al.  Structural determinants of sigma receptor affinity. , 1987, Molecular pharmacology.

[117]  P. Sastry,et al.  Lipids of nervous tissue: composition and metabolism. , 1985, Progress in lipid research.